Tumor-associated macrophage and T-cell subsets are implicated in the pathogenesis of diffuse large B-cell lymphoma, follicular lymphoma, and classical Hodgkin lymphoma. Macrophages provide essential mechanisms of tumor immune evasion through checkpoint ligand expression and secretion of suppressive cytokines. However, normal and tumor-associated macrophage phenotypes are less well characterized than those of tumor-infiltrating T-cell subsets, and it would be especially valuable to know whether the polarization state of macrophages differs across lymphoma tumor microenvironments. Here, an established mass cytometry panel designed to characterize myeloid-derived suppressor cells and known macrophage maturation and polarization states was applied to characterize B-lymphoma tumors and non-malignant human tissue. High-dimensional single-cell analyses were performed using dimensionality reduction and clustering tools. Phenotypically distinct intra-tumor macrophage subsets were identified based on abnormal marker expression profiles that were associated with lymphoma tumor types. While it had been proposed that measurement of CD163 and CD68 might be sufficient to reveal macrophage subsets in tumors, results here indicated that S100A9, CCR2, CD36, Slan, and CD32 should also be measured to effectively characterize lymphoma-specific tumor macrophages. Additionally, the presence of phenotypically distinct, abnormal macrophage populations was closely linked to the phenotype of intra-tumor T-cell populations, including PD-1 expressing T cells. These results further support the close links between macrophage polarization and T-cell functional state, as well as the rationale for targeting tumor-associated macrophages in cancer immunotherapies.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bovine serum albumin
Classical dendritic cells
Cytometry by time-of-flight
Diffuse large B-cell lymphoma
Effector memory CD45RApos
Granulocyte-colony stimulating factor
Granulocyte macrophage-colony stimulating factor
Macrophage polarized by IL-10
Macrophage polarized by IL-4
Macrophage polarized by TPP
Macrophage-colony stimulating factor
Myeloid-derived suppressor cells
Programmed cell death protein 1
Programmed death-ligand 1
Plasmacytoid dendritic cell
Reactive lymphoid hyperplasia
S100 calcium-binding protein A
Spanning-tree progression analysis of density-normalized events
T-distributed stochastic neighbor embedding
Cocktail including TNFα, Pam3CSK4, and prostaglandin E2
Regulatory T cell
Visualization of t-distributed stochastic neighbor embedding
Scott DW, Gascoyne RD (2014) The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14:517–534. https://doi.org/10.1038/nrc3774
Galati D, Corazzelli G, De Filippi R, Pinto A (2016) Dendritic cells in hematological malignancies. Crit Rev Oncol Hematol 108:86–96. https://doi.org/10.1016/j.critrevonc.2016.10.006
Tudor CS, Bruns H, Daniel C et al (2014) Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma. PLoS One 9:e114345. https://doi.org/10.1371/journal.pone.0114345
Chang KC, Huang GC, Jones D, Lin YH (2007) Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 13:6666–6672. https://doi.org/10.1158/1078-0432.CCR-07-0504
Mantovani A, Marchesi F, Malesci A et al (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399–416. https://doi.org/10.1038/nrclinonc.2016.217
Xue J, Schmidt SV, Sander J et al (2014) Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40:274–288. https://doi.org/10.1016/j.immuni.2014.01.006
Marini O, Spina C, Mimiola E et al (2016) Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget 7:27676–27688. https://doi.org/10.18632/oncotarget.8507
Azzaoui I, Uhel F, Rossille D et al (2016) T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood 128:1081–1092. https://doi.org/10.1182/blood-2015-08-662783
Kumar V, Patel S, Tcyganov E, Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37:208–220. https://doi.org/10.1016/j.it.2016.01.004
Ugel S, De Sanctis F, Mandruzzato S, Bronte V (2015) Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Investig 125:3365–3376. https://doi.org/10.1172/JCI80006
Chevrier S, Levine JH, Zanotelli VRT et al (2017) An immune atlas of clear cell renal cell carcinoma. Cell 169:736–738.e18. https://doi.org/10.1016/j.cell.2017.04.016
Wagner J, Rapsomaniki MA, Chevrier S et al (2019) A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell. https://doi.org/10.1016/j.cell.2019.03.005
Lavin Y, Kobayashi S, Leader A et al (2017) Innate Immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169:750–757.e15. https://doi.org/10.1016/j.cell.2017.04.014
Riihijarvi S, Fiskvik I, Taskinen M et al (2015) Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a nordic phase II trial. Haematologica 100:238–245. https://doi.org/10.3324/haematol.2014.113472
Hasselblom S, Hansson U, Sigurdardottir M et al (2008) Expression of CD68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 58:529–532. https://doi.org/10.1111/j.1440-1827.2008.02268.x
Shen L, Li H, Shi Y et al (2016) M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma. Sci Rep 6:30347. https://doi.org/10.1038/srep30347
Aldinucci D, Celegato M, Casagrande N (2016) Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Cancer Lett 380:243–252. https://doi.org/10.1016/j.canlet.2015.10.007
Greaves P, Clear A, Owen A et al (2013) Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 122:2856–2863. https://doi.org/10.1182/blood-2013-06-508044
Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875–885. https://doi.org/10.1056/NEJMoa0905680
Azambuja D, Natkunam Y, Biasoli I et al (2012) Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 23:736–742. https://doi.org/10.1093/annonc/mdr157
Kridel R, Steidl C, Gascoyne RD (2015) Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica 100:143–145. https://doi.org/10.3324/haematol.2015.124008
Roussel M, Ferrell PB, Greenplate AR et al (2017) Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow. J Leukoc Biol 102:437–447. https://doi.org/10.1189/jlb.5MA1116-457R
Fienberg HG, Simonds EF, Fantl WJ et al (2012) A platinum-based covalent viability reagent for single-cell mass cytometry. Cytom A 81:467–475. https://doi.org/10.1002/cyto.a.22067
Finck R, Simonds EF, Jager A et al (2013) Normalization of mass cytometry data with bead standards. Cytom A 83:483–494. https://doi.org/10.1002/cyto.a.22271
Diggins KE, Ferrell PB, Irish JM (2015) Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data. Methods 82:55–63. https://doi.org/10.1016/j.ymeth.2015.05.008
Roussel M, Bartkowiak T, Irish JM (2019) Picturing polarized myeloid phagocytes and regulatory cells by mass cytometry. Methods Mol Biol 1989:217–226. https://doi.org/10.1007/978-1-4939-9454-0_14
Kotecha N, Krutzik PO, Irish JM (2010) Web-based analysis and publication of flow cytometry experiments. Curr Protoc Cytom. https://doi.org/10.1002/0471142956.cy1017s53
Gravelle P, Péricart S, Tosolini M et al (2018) EBV infection determines the immune hallmarks of plasmablastic lymphoma. Oncoimmunology 7:e1486950. https://doi.org/10.1080/2162402X.2018.1486950
Vermi W, Micheletti A, Finotti G et al (2018) slan+ monocytes and macrophages mediate CD20-dependent B-cell lymphoma elimination via ADCC and ADCP. Can Res 78:3544–3559. https://doi.org/10.1158/0008-5472.CAN-17-2344
Bronte V, Brandau S, Chen S-H et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150. https://doi.org/10.1038/ncomms12150
Feng P-H, Lee K-Y, Chang Y-L et al (2012) CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med 186:1025–1036. https://doi.org/10.1164/rccm.201204-0636OC
Zhao F, Hoechst B, Duffy A et al (2012) S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 136:176–183. https://doi.org/10.1111/j.1365-2567.2012.03566.x
Chen X, Eksioglu EA, Zhou J et al (2013) Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Investig 123:4595–4611. https://doi.org/10.1172/JCI67580
Feng P-H, Yu C-T, Chen K-Y et al (2018) S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB. Oncotarget 9:7631–7643. https://doi.org/10.18632/oncotarget.24146
Vari F, Arpon D, Keane C et al (2018) Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 131:1809–1819. https://doi.org/10.1182/blood-2017-07-796342
McCord R, Bolen CR, Koeppen H et al (2019) PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv 3:531–540. https://doi.org/10.1182/bloodadvances.2018020602
Carey CD, Gusenleitner D, Lipschitz M et al (2017) Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420–2430. https://doi.org/10.1182/blood-2017-03-770719
Cader FZ, Schackmann RCJ, Hu X et al (2018) Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. Blood 132:825–836. https://doi.org/10.1182/blood-2018-04-843714
Yang Z-Z, Kim HJ, Villasboas JC et al (2019) Mass cytometry analysis reveals that specific intratumoral CD4+ T cell subsets correlate with patient survival in follicular lymphoma. Cell Rep 26:2178–2193.e3. https://doi.org/10.1016/j.celrep.2019.01.085
Wogsland CE, Greenplate AR, Kolstad A et al (2017) Mass cytometry of follicular lymphoma tumors reveals intrinsic heterogeneity in proteins including HLA-DR and a deficit in nonmalignant plasmablast and germinal center B-cell populations. Cytom B Clin Cytom 92:79–87. https://doi.org/10.1002/cyto.b.21498
Nissen MD, Kusakabe M, Wang X et al (2019) Single cell phenotypic profiling of 27 DLBCL cases reveals marked intertumoral and intratumoral heterogeneity. Cytom A 9:2579. https://doi.org/10.1002/cyto.a.23919
Leelatian N, Doxie DB, Greenplate AR et al (2017) Single cell analysis of human tissues and solid tumors with mass cytometry. Cytom B Clin Cytom 92:68–78. https://doi.org/10.1002/cyto.b.21481
Mistry AM, Greenplate AR, Ihrie RA, Irish JM (2018) Beyond the message: advantages of snapshot proteomics with single-cell mass cytometry in solid tumors. FEBS J. https://doi.org/10.1111/febs.14730
Giesen C, Wang HAO, Schapiro D et al (2014) Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 11:417–422. https://doi.org/10.1038/nmeth.2869
Chang Q, Ornatsky OI, Siddiqui I et al (2017) Imaging mass cytometry. Cytom A 91:160–169. https://doi.org/10.1002/cyto.a.23053
We are indebted to the clinicians of the BREHAT (Bretagne Réseau Expertise Hématologie) network and the CeVi collection from the Carnot/CALYM Institute (https://www.calym.org/-Collection-de-cellules-vivantes-CeVi-.html) funded by the ANR (Agence Nationale de la Recherche) for providing samples. The authors acknowledge the Centre de Ressources Biologiques (CRB) of Rennes (BB-0033-00056, https://www.crbsante-rennes.com) [Celine Pangault] and the CeVi network for managing samples.
This work was supported by research grants: National Institutes of Health/National Cancer Institute (NIH/NCI R00 CA143231, R01 CA226833, U54 CA217450, U01 AI125056), and the Vanderbilt-Ingram Cancer Center (VICC, P30 CA68485) [to Jonathan M. Irish]; Comité pour la recherche translationnelle (CORECT) from the University hospital at Rennes (Grant no. 2015) [to Faustine Lhomme]; and the CeVi collection from the Carnot/CALYM Institute (ANR) [to Camille Laurent and Mikael Roussel]. Mikael Roussel is recipient of a fellowship from the Nuovo-Soldati Fundation (Switzerland). Pauline Gravelle is supported by the CeVi collection from the Carnot/CALYM Institute.
Conflict of interest
Jonathan M. Irish was a co-founder and was a board member of Cytobank Inc. and received research support from Incyte Corp, Janssen, and Pharmacyclics. The authors declare that there are no other conflicts of interest.
Sample collection was performed in France (Rennes [all samples except HL #1, #2, #3, and #4] and through the CeVi_collection [HL #1, #2, #3, and #4]). CyTOF analysis was performed in Nashville, TN, USA by Mikael Roussel during a postdoctoral position in Jonathan Irish’s Lab at Vanderbilt University. Data analysis were performed in both sites (Rennes and Nashville). Multiplex IHC was performed in Toulouse (France).
Ethical approval and ethical standards
Samples were obtained under French legal guidelines and fulfilled the requirements of the University Hospital of Rennes institutional ethics committee for samples collected in Rennes (CRB) [approval number DC-2008-630 and DC-2016-2565] and of the Comité de Protection des Personnes for samples collected through the Cevi collection [approval number DC-2013-1783].
Tissue from patients was acquired with informed consent in accordance with local institutional review and the Declaration of Helsinki. A written consent was obtained from patients before qualification for research in the CRB or the CeVI collection. The consent was for the use of their specimens and data for research and for publication.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Roussel, M., Lhomme, F., Roe, C.E. et al. Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas. Cancer Immunol Immunother 69, 407–420 (2020). https://doi.org/10.1007/s00262-019-02464-z
- Germinal center
- Tumor-associated macrophages
- Mass cytometry